Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.The company also noted a cash position of $85.2 million as of December 31, 2025, which it expects to sustain operations into the second half of 2028.Tumultuous 2025 For KorroChardan Research wrote that 2025 was a tumultuous year for Korro.After building momentum from June to October, the company suffered a considerable setback i ...